Streetwise Reports' Article Archives — Current Month (6)
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market (07/02/2026)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains.
Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity (07/02/2026)
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.
Satellos Bioscience Fast Track Win Fuels DMD Hopes (07/02/2026)
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.
Digital Health Pioneer Targets Massive Breakthrough Chronic Care Market (07/01/2026)
AI-driven digital health solutions pioneer DarioHealth Corp. (DRIO:NASDAQ) announces a partnership that it says will give it access to a network spanning all 50 states. Find out why analysts like the direction the company is taking.
DarioHealth (DRIO) Expands Reach via Beluga Health Deal (07/01/2026)
DarioHealth (DRIO) integrates its AI platform with Beluga Health's network to scale provider-backed care. Discover growth catalysts, analyst targets, and investor considerations.
Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings (07/01/2026)
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial.
More Archives
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
